Physician profile
Dmitriy Kolesnik
NPI 1851326367
$8,076.61
in general payments reported to CMS, 2019-2025
50 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $427 · 2021: $1,110 · 2022: $1,172 · 2023: $1,537 · 2024: $1,528 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,907 · Consulting Fee: $150 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.60 |
| Consulting Fee | $150.00 |
| Education | $108.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.37 | 2021-2025 | |
| Ucb, INC. | $875.61 | 2019-2025 | Nayzilam, Fintepla, Briviact |
| Scilex Pharmaceuticals INC. | $550.92 | 2023-2025 | Ztlido |
| Eisai INC. | $549.86 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $541.35 | 2020-2025 | Xywav, Epidiolex |
| Sk Life Science, INC. | $448.88 | 2020-2024 | |
| Neurelis, INC. | $310.91 | 2021-2024 | Valtoco |
| Amgen INC. | $305.99 | 2019-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $293.78 | 2019-2021 | |
| Lundbeck LLC | $274.51 | 2019-2025 | Vyepti |
| Otsuka America Pharmaceutical, INC. | $219.61 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Pfizer INC. | $215.82 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $174.60 | 2023-2024 | Aptiom |
| Harmony Biosciences LLC | $168.39 | 2023-2025 | Wakix |
| Collegium Pharmaceutical, INC. | $155.47 | 2019-2023 | Xtampza |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Kolesnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.